4.8 Article

RetroCHMP3 blocks budding of enveloped viruses without blocking cytokinesis

Journal

CELL
Volume 184, Issue 21, Pages 5419-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2021.09.008

Keywords

-

Funding

  1. NIH [R37 AI 51174, P50 AI150464, K01 OD030059, AI121880]
  2. NIH/NIGMS [5R01GM119585]
  3. USDA NIFA [1010021]
  4. Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award
  5. Pew Charitable Trusts Innovation Fund Award
  6. NIFA [913560, 1010021] Funding Source: Federal RePORTER

Ask authors/readers for more resources

Duplicated and truncated copies of the ESCRT-III factor CHMP3 have been found in New World monkeys and mice, which can block virus budding. These new retroCHMP3 proteins have evolved to reduce interactions with other ESCRT-III factors, providing a new route for inhibiting the release of various viruses.
Many enveloped viruses require the endosomal sorting complexes required for transport (ESCRT) pathway to exit infected cells. This highly conserved pathway mediates essential cellular membrane fission events, which restricts the acquisition of adaptive mutations to counteract viral co-option. Here, we describe dupli cated and truncated copies of the ESCRT-III factor CHMP3 that block ESCRT-dependent virus budding and arose independently in New World monkeys and mice. When expressed in human cells, these retroCHMP3 proteins potently inhibit release of retroviruses, paramyxoviruses, and filoviruses. Remarkably, retroCHMP3 proteins have evolved to reduce interactions with other ESCRT-III factors and have little effect on cellular ESCRT processes, revealing routes for decoupling cellular ESCRT functions from viral exploitation. The re purposing of duplicated ESCRT-III proteins thus provides a mechanism to generate broad-spectrum viral budding inhibitors without blocking highly conserved essential cellular ESCRT functions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biology

Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A

Cristina Olivieri, Caitlin Walker, Adak Karamafrooz, Yingjie Wang, V. S. Manu, Fernando Porcelli, Donald K. Blumenthal, David D. Thomas, David A. Bernlohr, Simon M. Sandford, Susan S. Taylor, Gianluigi Veglia

Summary: The fusion of the dynamic J-domain to PKA-C disrupts the internal allosteric network, causing attenuation of nucleotide/PKI binding cooperativity. This reduced allosteric cooperativity alters specific recognitions and interactions between substrates and regulatory partners, contributing to dysregulation exhibited by PKA-C-DNAJB1.

COMMUNICATIONS BIOLOGY (2021)

Article Pathology

Morphologic and Molecular Findings in Myxoid Hepatic Adenomas

Daniel J. Rowan, Saba Yasir, Zongming E. Chen, Taofic Mounajjed, Sibel Erdogan Damgard, Lisa Cummins, Lizhi Zhang, Emma Whitcomb, Vince Falck, Sanford M. Simon, Aatur D. Singhi, Michael S. Torbenson

Summary: Myxoid hepatic adenomas are a rare subtype of hepatic adenomas that predominantly occur in older individuals and have an elevated risk of malignant transformation. They are characterized by the combined inactivation of HNF1A and additional mutations that cluster in the PKA pathway.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

Article Virology

Paramyxovirus-Like Particles as Protein Delivery Vehicles

Santosh Panthi, Phuong Tieu Schmitt, F. Jeffrey Lorenz, Brent A. Stanfield, Anthony P. Schmitt

Summary: A flexible platform for protein delivery to target cell interiors using paramyxovirus-like particles has been developed, enabling efficient cargo packaging and delivery to target cells. This approach holds promise for safe and efficient delivery of therapeutic proteins to cells and tissues, addressing current limitations in protein delivery for potential clinical applications.

JOURNAL OF VIROLOGY (2021)

Article Oncology

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening

Gadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, Denise Ng, Patrick D. Bhola, Ype P. de Jong, Ruisi Wang, Nicole J. C. Narayan, Bassem Shebl, Solomon Levin, Eleftherios Michailidis, Mohammad Kabbani, Koen O. A. Vercauteren, Arlene M. Hurley, Benjamin A. Farber, William J. Hammond, James A. Saltsman, Ethan M. Weinberg, J. Fraser Glickman, Barbara A. Lyons, Jessica Ellison, Erik Schadde, Martin Hertl, Jennifer L. Leiting, Mark J. Truty, Rory L. Smoot, Faith Tierney, Tomoaki Kato, Hans-Guido Wendel, Michael P. LaQuaglia, Charles M. Rice, Anthony Letai, Philip Coffino, Michael S. Torbenson, Michael Ortiz, Sanford M. Simon

Summary: Therapeutics informed by genomics have not been effective for fibrolamellar carcinoma (FLC). A functional drug screen identified that inhibitors of TOPO1 and HDAC, along with napabucasin, showed efficacy on patient-derived xenografts (PDX) of FLC. Inhibiting Bcl-xL in combination with these drugs also showed synergy in treating FLC.

CANCER DISCOVERY (2021)

Article Biochemistry & Molecular Biology

Recurrent evolution of an inhibitor of ESCRT-dependent virus budding and LINE-1 retrotransposition in primates

Lara Rheinemann, Diane Miller Downhour, Kristen A. Davenport, Alesia N. McKeown, Wesley Sundquist, Nels C. Elde

Summary: Most antiviral proteins recognize specific features of viruses, but retroCHMP3 interferes with the host endosomal complexes pathway to inhibit enveloped virus budding. The ESCRT pathway is essential for cellular membrane fission reactions, so ESCRT inhibition can be cytotoxic. Research on New World monkeys shows the evolutionary process of detoxification for retroCHMP3, providing insights into potential future antiviral defense mechanisms in modern species.

CURRENT BIOLOGY (2022)

Article Cell & Tissue Engineering

Human liver organoids for disease modeling of fibrolamellar carcinoma

Nicole J. C. Narayan, David Requena, Gadi Lalazar, Lavoisier Ramos-Espiritu, Denise Ng, Solomon Levin, Bassem Shebl, Ruisi Wang, William J. Hammond, James A. Saltsman III, Helmuth Gehart, Michael S. Torbenson, Hans Clevers, Michael P. LaQuaglia, Sanford M. Simon

Summary: In this study, patient-derived organoids were successfully developed and used as a model system to recapitulate the histologic morphology, immunohistochemistry, and transcriptome of fibrolamellar carcinoma (FLC). This model system shows promise for improving our understanding of this rare cancer and for drug testing and development.

STEM CELL REPORTS (2022)

Article Oncology

Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA

Christoph Neumayer, Denise Ng, Caroline S. Jiang, Adam Qureshi, Gadi Lalazar, Roger Vaughan, Sanford M. Simon

Summary: The fusion gene DNAJB1-PRKACA is found to be a recurrent mutation in fibrolamellar hepatocellular carcinoma (FLC). Continued expression of DNAJB1-PRKACA is essential for tumor growth and its inhibition can lead to cell death. This discovery has implications for investigating other fusion genes in pediatric cancers and advancing precision therapies.

CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Single molecule microscopy reveals diverse actions of substrate sequences that impair ClpX AAA plus ATPase function

Xiao Wang, Sanford M. Simon, Philip Coffino

Summary: This study used single molecule experiments to measure the dwell time of substrates interacting with the AAA+ ATPase unfoldase/translocase ClpX, finding that tail length and composition of the substrates affect substrate retention during futile unfolding. Both polyG and GAr have inhibitory effects on unfolding, but act differently.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Article Medicine, Research & Experimental

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

Bassem Shebl, Denise Ng, Gadi Lalazar, Carly Rosemore, Tova M. Finkelstein, Rachael D. Migler, Guangrong Zheng, Peiyi Zhang, Caroline S. Jiang, Adam Qureshi, Roger Vaughan, Mark Yarchoan, Ype P. de Jong, Charles M. Rice, Philip Coffino, Michael V. Ortiz, Daohong Zhou, Sanford M. Simon

Summary: Fibrolamellar hepatocellular carcinoma (FLC) is a rare and lethal liver cancer with no effective systemic therapy. Inhibiting the antiapoptotic protein BCL-XL has shown synergy with various systemic therapies for FLC cells in vitro. However, the physiological expression of BCL-XL in platelets has hindered previous attempts to target this vulnerability in other cancers.

JCI INSIGHT (2022)

Review Oncology

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

Sanford M. Simon

Summary: The fight against rare cancers is challenged by issues such as misdiagnosis, lack of information and tools, limited samples, and inadequate funding. However, studying rare cancers has led to important discoveries in cancer biology, such as the identification of tumor suppressor genes. Fibrolamellar hepatocellular carcinoma (FLC) is a rare and difficult-to-diagnose liver cancer that primarily affects young individuals. Through a personal journey, Sanford Simon shares insights into whether FLC is a single cancer type or a collection of similar phenotypes, and its genetic inheritance or somatic mutation origins.

NATURE REVIEWS CANCER (2023)

Article Gastroenterology & Hepatology

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study

Amichai Berkovitz, Rachael D. Migler, Adam Qureshi, Carly Rosemore, Michael S. Torbenson, Roger Vaughan, Erin Marcotte, Sanford M. Simon

Summary: Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary liver cancer primarily affecting adolescents and young adults. Female gender is associated with improved survival, while the presence of 10 or more tumors within the liver and metastases at diagnosis are associated with worse survival. This study utilized a patient community-based FLC registry to highlight the importance of rare tumor registries in advancing clinical and scientific discoveries.

HEPATOLOGY COMMUNICATIONS (2022)

No Data Available